PMID-28422855 – Thymalfasin Adjuvant After HCC Liver Resection
He C et al. "The prognostic value of thymalfasin for patients with hepatocellular carcinoma after hepatectomy," Medicine, 2017;96(20):e6904.
Quick Reference
| Property | Value |
|---|---|
| PMID | 28422855 |
| DOI | N/A |
| Year | 2017 |
| Journal | Medicine |
| Study Type | Retrospective Observational |
| Evidence Level | III |
| Sample | n=206 HCC patients after hepatectomy |
| Peptide(s) Studied | Thymosin Alpha-1 (thymalfasin) |
Key Findings
- Patients receiving adjuvant thymalfasin after curative hepatectomy for HCC demonstrated significantly improved 5-year overall survival: 82.9% vs 62.9% in the control group
- Recurrence-free survival was also significantly improved in the thymalfasin group
- Thymalfasin administration was associated with enhanced post-operative immune recovery, including improved CD4+/CD8+ T-cell ratios
- The survival benefit was most pronounced in patients with larger tumors and those with more advanced disease stages
- Multivariate analysis confirmed thymalfasin as an independent predictor of improved overall survival after adjusting for tumor size, vascular invasion, and AFP levels
- The treatment was well tolerated with no significant additional adverse events compared to standard post-operative care
Study Design
Single-center retrospective cohort study comparing outcomes of HCC patients who received adjuvant thymalfasin (1.6 mg subcutaneously, twice weekly for 6-12 months) after curative hepatectomy vs matched controls who received standard post-operative care without thymalfasin. Primary endpoints were 5-year overall survival and recurrence-free survival.
Limitations
- Retrospective non-randomized design with inherent selection bias
- Single-center study limits generalizability
- No standardized protocol for thymalfasin duration (6-12 months)
- Propensity score matching not employed; multivariate analysis used instead
- Historical controls may reflect differences in surgical technique and supportive care over time
Clinical Relevance
This study provides real-world evidence supporting thymosin alpha-1 as an adjuvant immunotherapy after curative HCC resection. The 20 percentage-point improvement in 5-year OS (82.9% vs 62.9%) is clinically meaningful, particularly given the high recurrence rates of HCC after surgery. The favorable safety profile and immune-enhancing mechanism make thymalfasin an attractive addition to post-surgical management. While a prospective RCT is needed for definitive evidence, this data supports considering thymosin alpha-1 in the post-hepatectomy setting.
Related
#research #observational #evidence-level-III #cancer